JeffGeschwind

Introduction Liver cancer, particularly hepatocellular carcinoma (HCC), remains one of the most lethal cancers worldwide. As the global burden increases, interventional oncology has risen as a central pillar of modern cancer care. Among the most effective minimally invasive treatments is Transarterial Chemoembolization (TACE) , a targeted therapy designed to cut off the tumor’s blood supply while delivering concentrated chemotherapy directly to the malignant tissue. While TACE has been used for decades, its precision and reliability have dramatically improved with the arrival of Cone Beam CT (CBCT) — a technology that enables three-dimensional imaging inside the angiography suite. One of the leading figures responsible for championing the clinical significance of CBCT during TACE is Dr. Jeff Geschwind , a global authority in interventional oncology and liver cancer research. This article examines how Dr. Geschwind’s work has influenced clinical standards, enhanced therapeutic ac...

Geschwind tumor metabolism represents one of the most influential scientific frameworks in modern oncology, shaping how clinicians understand the biochemical behavior of cancer. Tumor metabolism has moved from a peripheral research theme to a central driver of personalized cancer therapy. Professor Jeff Geschwind’s work has been pivotal in connecting metabolic reprogramming with therapeutic design, diagnostic imaging, and procedural oncology, opening new directions for targeted interventions. This article explores how Geschwind’s metabolic principles are transforming cancer care, enabling early detection, precise classification, and innovative therapies that disrupt cancer’s metabolic dependencies. Understanding Tumor Metabolism Cancer metabolism describes the biochemical processes that fuel tumor growth, progression, angiogenesis, and metastasis. While healthy cells maintain balanced metabolic pathways, cancer cells modify these pathways to meet the high energy and biosynthetic ...